Request availability and a quotation for your required quantity and destination.
| Product | Semaglutide 14 mg - Rybelsus Tablet |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Semaglutide 14 mg
Dosage form: Oral tablet
Drug class: GLP-1 receptor agonist
Prescription: Required
Rybelsus 14 mg is an oral semaglutide medicine used to improve blood glucose control in adults with type 2 diabetes, together with diet and physical activity. The 14 mg strength is a higher maintenance-dose option when further glycaemic control is needed after treatment with 7 mg. Treatment must be selected and monitored by a clinician. This is not insulin and it is not intended to treat type 1 diabetes.
Oral semaglutide improves glycaemic control in adults with type 2 diabetes when prescribed appropriately. Its GLP-1 receptor activity stimulates glucose-dependent insulin release, reduces glucagon and delays gastric emptying. Weight changes can occur, but this page does not present Rybelsus as an independently approved weight-loss medicine; indications differ by jurisdiction.
In the Rybelsus 3/7/14 mg formulation, a prescriber may consider 14 mg once daily when additional blood-glucose control is needed after at least 30 days on 7 mg. Do not increase the dose yourself. Different oral semaglutide formulations and branded tablets are not interchangeable milligram-for-milligram. Follow the pack-specific label.
Take as prescribed in the morning on an empty stomach, with plain water only (no more than 120 mL/4 fl oz). Swallow the tablet whole; do not crush, split or chew. Wait at least 30 minutes before food, other drinks or other oral medications. Taking it with food or too much water can reduce absorption. Ask your prescriber for advice on missed doses and other medicines.
Common effects include nausea, diarrhoea, vomiting, constipation and abdominal discomfort. Dehydration may worsen kidney problems. Important warnings include pancreatitis, gallbladder disease, diabetic retinopathy complications and low blood sugar when combined with insulin or sulfonylureas. Seek urgent care for severe ongoing abdominal pain or signs of a serious allergic reaction.
Important contraindications: In U.S. labeling, semaglutide is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and those with serious hypersensitivity to semaglutide. Discuss pregnancy plans, other medicines and individual medical risks with your clinician.
Explore Rybelsus 3 mg, Rybelsus 7 mg and Rybelsus 14 mg. Read Cureiva’s educational article, Related Cureiva readingRybelsus 3 mg vs 7 mg vs 14 mg, for an explanation of titration and safety.
See the U.S. DailyMed prescribing information for oral semaglutide. Always consult the official label for the exact formulation and country.
Rybelsus tablets are generally taken once daily as prescribed. Check the product-specific instructions for the exact formulation.
No. It is taken upon waking on an empty stomach with a small amount of plain water, followed by a wait of at least 30 minutes before eating.
No. Tablet formulations and injectable semaglutide have different dose schedules; changing medicines requires a prescriber’s supervision.
Rybelsus is used for type 2 diabetes; approved indications vary by country. A qualified clinician should assess weight-management treatment separately.
Yes, enquiries are reviewed subject to availability, prescription requirements and destination-country import rules. Enquiring does not guarantee supply.
For the 3/7/14 mg formulation, skip the missed dose and take the next tablet the following day; do not double the dose.
No. For this formulation, 14 mg may be considered after at least 30 days at 7 mg when additional glycaemic control is needed, under a prescriber’s direction.
Do not substitute or combine tablets to change your prescribed dose without checking the product leaflet and your prescriber.
Hypoglycaemia risk can rise when semaglutide is used with insulin or sulfonylureas. Your clinician may need to review the regimen.
Seek urgent help for severe persistent abdominal pain, serious allergic symptoms, or severe vomiting with dehydration.
Cureiva Healthcare provides medicine information and handles wholesale and individual patient enquiries where legally permitted. Product supply requires appropriate documentation and regulatory compliance. This educational page does not replace medical advice or prescribing information.
Information checked: October 2026. No individual clinician review is claimed.